Vyant Bio, Inc. (VYNT)
| Market Cap | 22.21M |
| Revenue (ttm) | 1.23M |
| Net Income (ttm) | -42.66M |
| Shares Out | 29.41M |
| EPS (ttm) | 1.32 |
| PE Ratio | 0.57 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 15,983 |
| Open | 0.795 |
| Previous Close | 0.790 |
| Day's Range | 0.760 - 0.795 |
| 52-Week Range | 0.600 - 3.240 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 3.06 (+305.3%) |
| Earnings Date | Aug 15, 2022 |
About VYNT
Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to... [Read more...]
Financial Performance
In 2021, Vyant Bio's revenue was $1.15 million, an increase of 32.41% compared to the previous year's $867,000. Losses were -$40.86 million, 372.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for VYNT stock is "Buy." The 12-month stock price forecast is 3.06, which is an increase of 305.30% from the latest price.
News
Vyant Bio Announces Rescheduled Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopm...
Vyant Bio Postpones Second Quarter Investor Conference Call and Webcast
CHERRY HILL, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopm...
Vyant Bio Announces Investor Conference Call and Webcast for the Second Quarter and First Half of 2022
CHERRY HILL, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopm...
Vyant Bio to Present at Investor Summit Group's Q3 Virtual Conference
Cherry Hill, New Jersey--(Newsfile Corp. - August 3, 2022) - Vyant Bio, Inc. (NASDAQ: VYNT) ("Vyant Bio" or "Company") is an innovative biotechnology company reinventing drug discovery for complex neuro...
Vyant Bio Retains Skyline Corporate Communications Group, LLC to Provide Investor Relations Services
CHERRY HILL, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopm...
Vyant Bio Reports First Quarter 2022 Results and Provides Strategic and Business Highlights
Conference Call and Webcast Today at 4:30 pm ET
Vyant Bio Announces Investor Conference Call and Webcast for the First Quarter 2022
CHERRY HILL, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT) is an innovative biotechnology company reinventing drug discovery for complex neurodevelopment...
Vyant Bio Announces Participation in BioNJ's 12th Annual BioPartnering Conference
CHERRY HILL, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug discovery for complex neurodevelopmental...
Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?
Penny stocks are a hot subject today with several of the top companies in the market seeing major gains on Wednesday and we know why! The post Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GER...
Vyant Bio Shares Jump On Parkinson's Disease Agreement
Vyant Bio Inc (NASDAQ: VYNT) and OrganoTherapeutics have entered into a collaboration agreement to work toward accelerating the discovery of drugs for the treatment of Parkinson's Disease. Specific deal...
Vyant Bio and OrganoTherapeutics Announce Strategic Collaboration to Discover Therapeutics to Treat Parkinson's Disease
Cherry Hill, N.J. and Esch-sur-Alzette, Luxembourg, March 29, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an innovative biotechnology company reinventing drug disco...
Vyant Bio Announces Investor Conference Call and Webcast for the Year-End 2021
CHERRY HILL, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is an innovative biotechnology company reinventing drug discovery for complex neurodevelopm...
Vyant Bio Issues Letter to Shareholders
Cherry Hill, NJ, March 01, 2022 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nadsaq:VYNT), is an innovative biotechnology company focused on identifying unique biological targets an...
Vyant Bio to Present at The Benchmark Company Discovery One-on-One Investor Conference
Cherry Hill, N.J.,, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molec...
Vyant Bio Reports Third Quarter 2021 Results and Provides Strategic Business Updates
Strategic Highlights
Vyant Bio to Present at the Q4 Investor Summit Micro & Small Cap Conference
Cherry Hill, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule t...
Vyant Bio Announces Investor Conference Call and Webcast for the Third Quarter 2021
CHERRY HILL, N.J., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Vyant Bio , Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule ...
Vyant Bio and Cyclica Announce a Strategic Collaboration to Identify Compounds to Treat CDKL5 Deficiency Disorder
CHERRY HILL, NJ and TORONTO, CANADA, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc., (Nasdaq: VYNT), a leading biotech company discovering new therapeutics for neurological diseases and hard-to-treat...
Vyant Bio Announces Investor Conference Call and Webcast for Second Quarter 2021
CHERRY HILL, N.J., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), an emerging global drug discovery company, is rapidly identifying small and large molecule t...
Vyant Bio Announces Issuance of Key Patent for High-Throughput Optical Assay of Human Mixed Cell Population Spheroids
CHERRY HILL, N.J., July 13, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, the “Company”) (Nasdaq: VYNT), an emerging leader in novel drug discovery technologies, announced today that its wholly...
Vyant Bio Reports First Quarter 2021 Results and Provides Strategic Business Update
Cherry Hill, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (the “Company”) (Nasdaq: VYNT), is an innovative biotechnology company focused on partnering with pharmaceutical and other biotechnolo...
Vyant Bio to Present at BioNJ's 11th Annual BioPartnering Conference
CHERRY HILL, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio”, “Company”) (Nasdaq: VYNT), is a new force in drug discovery, focused on integrating human-powered scientific and technol...
3 Short Squeeze Candidates In The Health Care Sector
Low float stocks can be some of the most volatile stocks in the market. If you mix in a short squeeze, the potential short-term gains in a low float stock can be extreme.